title: Serum interferon-gamma-inducible protein-10 concentrations and IL28B genotype associated with responses to pegylated interferon plus ribavirin with and without telaprevir for chronic hepatitis C.
abstract: OBJECTIVE
  Several studies have shown that high pretreatment concentrations of serum interferon-γ-inducible protein-10 (IP-10) are correlated with non-response to pegylated interferon (PEG-IFN) plus ribavirin (RBV) for chronic hepatitis C (CHC). However, there are few reports on their effect on the Asian population.
  
  
  METHODS
  We enrolled 104 Japanese genotype 1 CHC individuals treated with PEG-IFN/RBV and 45 with PEG-IFN/RBV/telaprevir, and evaluated the impact of pretreatment serum IP-10 concentrations on their virological responses.
  
  
  RESULTS
  The pretreatment serum IP-10 concentrations were not correlated with IL28B genotype. The receiver-operator curve analysis determined the cut-off value of IP-10 for predicting a sustained virological response (SVR) as 300 pg/mL. In multivariate analysis, the IL28B favorable genotype and IP-10 concentration of less than 300 pg/mL were independent factors for predicting SVR. In a subgroup of patients with the IL28B favorable genotype, the SVR rate was higher in the patients with IP-10 of less than 300 than in those with 300 pg/mL or more, whereas no patient with the IL28B unfavorable genotype and IP-10 of 300 pg/mL or more achieved SVR. Among the patients treated with PEG-IFN/RBV/telaprevir, low pretreatment concentrations of serum IP-10 were associated with a very rapid virological response, defined as undetectable HCV RNA at week 2 after the start of therapy.
  
  
  CONCLUSIONS
  Pretreatment serum IP-10 concentrations are associated with treatment efficacy in PEG-IFN/RBV and with early viral kinetics of hepatitis C virus in PEG-IFN/RBV/telaprevir therapy.
authors.affiliation: Department of Virology, Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan; Infectious Disease and Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, USA.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Matsuura
authors.forename: Tsunamasa
authors.initials: T
authors.lastname: Watanabe
authors.forename: Sayuki
authors.initials: S
authors.lastname: Iijima
authors.forename: Shuko
authors.initials: S
authors.lastname: Murakami
authors.forename: Kei
authors.initials: K
authors.lastname: Fujiwara
authors.forename: Etsuro
authors.initials: E
authors.lastname: Orito
authors.forename: Etsuko
authors.initials: E
authors.lastname: Iio
authors.forename: Mio
authors.initials: M
authors.lastname: Endo
authors.forename: Atsunori
authors.initials: A
authors.lastname: Kusakabe
authors.forename: Noboru
authors.initials: N
authors.lastname: Shinkai
authors.forename: Tomokatsu
authors.initials: T
authors.lastname: Miyaki
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Nojiri
authors.forename: Takashi
authors.initials: T
authors.lastname: Joh
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Tanaka
keywords: IL28B; hepatitis C; interferon; interferon-γ-inducible protein-10; ribavirin; telaprevir